recurr
respiratori
tract
infect
rti
signific
health
socioeconom
impact
recurr
infect
upper
lower
respiratori
tract
often
requir
multipl
treatment
modal
includ
use
antibiot
high
incid
diseas
combin
substanti
morbid
clinic
sequela
associ
overus
misus
antibiot
contribut
toward
overal
diseas
burden
includ
direct
cost
healthcar
indirect
econom
cost
societi
vast
major
recurr
rti
trigger
virus
frequent
follow
bacteri
superinfect
extens
literatur
synergist
effect
virus
bacteria
pathogenesi
respiratori
infect
regardless
whether
viral
bacteri
presenc
pathogen
respiratori
tract
trigger
involv
innat
adapt
mucos
immun
system
innat
mucos
immun
relat
function
epitheli
line
respiratori
tract
includ
product
antimicrobi
peptid
cytotox
action
nk
cell
engulf
pathogen
monocytesmacrophag
neutrophil
key
event
among
action
acquir
immun
system
product
iga
molecul
patient
impair
immun
chronic
inflamm
greater
risk
rti
especi
true
underli
condit
allerg
rhiniti
asthma
chronic
obstruct
pulmonari
diseas
copd
disord
highli
preval
worldwid
great
public
health
concern
patient
disord
impair
immunolog
respons
mechan
preponder
respons
reduct
protect
respons
furthermor
increas
level
ige
antibodi
relat
stronger
inflammatori
respons
prevent
clinic
point
view
need
address
recurr
sever
rti
larg
patient
popul
immunomodul
compris
lyophil
bacteri
lysat
eight
major
strain
respons
rti
haemophilu
influenza
streptococcu
pneumonia
klebsiella
pneumonia
klebsiella
ozaena
staphylococcu
aureu
streptococcu
pyogen
streptococcu
viridan
moraxella
catarrhali
pleiotrop
immunomodul
effect
innat
adapt
immun
respons
extens
bodi
evid
show
safeti
efficaci
prevent
rti
children
adult
regardless
etiolog
includ
impair
immun
use
shown
benefici
effect
incid
durat
sever
rti
aim
studi
evalu
efficaci
reduc
incid
rti
patient
allerg
rhiniti
asthma
copd
effect
immunolog
paramet
name
serum
secretori
iga
level
openlabel
prospect
sequenti
studi
conduct
total
consecut
patient
present
three
respiratori
infect
previou
year
elig
accord
inclus
exclus
criteria
provid
written
inform
consent
includ
among
patient
allerg
rhiniti
asthma
copd
patient
underw
complet
medic
histori
well
test
specif
serum
ige
allergen
skin
prick
test
serum
iga
salivari
secretori
iga
iga
level
test
month
month
observ
group
patient
reassess
patient
present
respiratori
infect
despit
optim
standard
care
regimen
standard
optim
care
soc
receiv
prophylaxi
bacteri
lysat
includ
second
phase
studi
patient
receiv
treatment
bacteri
lysat
alongsid
soc
evalu
manner
previou
year
studi
protocol
approv
institut
ethic
committe
written
inform
consent
obtain
particip
includ
studi
studi
conduct
accord
principl
declar
helsinki
amend
studi
includ
male
femal
outpati
age
year
confirm
histori
perenni
year
allerg
rhiniti
asthma
copd
least
three
rti
previou
year
assess
screen
visit
patient
allerg
rhiniti
asthma
elev
serum
ige
level
addit
patient
allerg
rhiniti
asthma
posit
skin
prick
test
one
follow
allergen
dermatophagoid
cat
dander
alternaria
andor
aspergillu
key
exclus
criteria
includ
structur
alter
nasal
pyramid
presenc
underli
medic
condit
could
interfer
studi
result
pregnanc
breastfeed
month
observ
soc
therapi
patient
receiv
treatment
one
mg
capsul
daili
ten
consecut
day
per
month
month
followedup
month
treatment
period
fig
addit
healthi
subject
underli
asthma
allergi
copd
occasion
visit
clinic
uncompl
respiratori
infect
select
normal
control
measur
iga
valu
rti
defin
viral
bacteri
infect
upper
lower
respiratori
tract
exacerb
asthma
defin
acut
subacut
episod
progress
worsen
short
breath
cough
wheez
andor
chest
tight
accompani
decreas
expiratori
airflow
lung
function
rhiniti
exacerb
consid
increas
typic
symptom
inflamm
nasal
membran
accompani
sneez
nasal
congest
nasal
itch
andor
rhinorrhea
exacerb
copd
defin
increas
dyspnea
sputum
volum
andor
sputum
purul
without
accompani
cough
wheez
symptom
upper
rti
clinic
symptom
assess
investig
accord
standard
symptom
score
studi
baselin
visit
end
soc
period
end
prophylaxi
followup
event
respiratori
infect
case
rti
patient
advis
visit
clinic
symptom
score
underli
diseas
asthma
rhiniti
copd
also
report
patient
follow
score
system
use
symptom
symptom
mild
rhiniti
mild
dyspnea
without
nocturn
symptom
alter
qualiti
life
daili
activ
need
extra
medic
peak
flow
predict
variabl
symptom
moder
rhiniti
moder
dyspnea
time
per
week
nocturn
symptom
affect
abil
work
attend
school
disappear
symptom
singl
extra
dose
medic
peak
flow
predict
variabl
symptom
sever
rhiniti
obstruct
dyspnea
three
time
per
day
nocturn
symptom
twice
week
ie
sleep
disturb
asthenia
abil
attend
work
school
affect
peak
flow
predict
variabl
patient
rigor
train
record
score
includ
peak
flow
measur
measur
iga
level
perform
period
soc
treatment
well
period
prophylaxi
iga
level
obtain
separ
group
healthi
adult
use
control
unstimul
parotid
saliva
sampl
ml
collect
salivett
sampl
devic
compos
cotton
roll
impregn
saliva
centrifug
obtain
transpar
saliva
sampl
analyz
sampl
store
analysi
secretori
iga
measur
mean
mancini
radial
immunodiffus
agar
sa
hereman
buffer
ph
use
monospecif
antiserum
human
colostrum
use
standard
mg
specif
ige
measur
confirm
involv
allerg
compon
patient
rhiniti
asthma
rule
allerg
involv
copd
patient
radioallergosorb
test
rast
consist
incub
patient
serum
sampl
allergen
coval
bound
paper
disk
antibodi
sampl
allergen
bind
solid
phase
incub
h
solid
phase
wash
three
time
wash
solut
remov
nonspecif
bound
antibodi
immedi
sampl
incub
antiig
antiserum
label
h
room
temperatur
afterward
disk
wash
remain
radioact
measur
use
gamma
counter
allergenspecif
ige
level
determin
compar
sampl
count
per
minut
standard
count
per
minut
accord
follow
qualit
classif
undetect
low
moder
high
high
extrem
high
note
normal
specif
ige
level
express
kul
uml
numer
valu
class
posit
neg
nonsensit
person
undetect
level
specif
ige
ige
absent
ige
said
neg
present
said
posit
tabl
depict
frequent
use
threshold
valu
specif
ige
level
found
patient
asthma
rhiniti
without
copd
shown
tabl
initi
sampl
patient
deem
necessari
order
detect
potenti
trend
nasal
immunolog
respons
detect
potenti
differ
exacerb
healthi
control
patient
attribut
studi
treatment
andor
underli
medic
condit
type
error
statist
power
pre
posttreat
differ
evalu
variabl
interest
describ
studi
group
ie
allerg
rhiniti
asthma
copd
chang
serum
salivari
secretori
iga
level
assess
symptom
score
underli
patholog
determin
descript
total
number
rti
experienc
patient
depict
tabl
fig
year
prior
studi
start
patient
report
total
rti
tabl
adjust
concurr
background
medic
soc
patient
cohort
report
total
rti
correspond
reduct
ad
prophylaxi
patient
report
rti
correspond
reduct
compar
previou
year
p
fig
number
rti
subdivid
report
patient
copd
asthma
allerg
rhiniti
fig
copd
patient
number
infect
reduct
asthmarhin
group
reduct
treatment
compar
previou
studi
year
tabl
exacerb
underli
diseas
patholog
compar
report
tabl
correspond
reduct
fig
patient
treat
alongsid
soc
time
exacerb
compar
exacerb
report
correspond
addit
reduct
compar
p
fig
number
exacerb
subdivid
report
patient
copd
asthma
allerg
rhiniti
fig
copd
patient
show
reduct
number
exacerb
correspond
reduct
asthma
allerg
rhiniti
show
reduct
treatment
year
tabl
result
overal
studi
period
summar
tabl
tabl
show
patient
symptom
score
year
receiv
soc
compar
follow
year
receiv
treatment
soc
tabl
indic
number
patient
report
score
treatment
soc
soc
plu
prophylaxi
within
categori
symptom
sever
rang
one
symptom
lower
proport
patient
report
score
year
receiv
prevent
treatment
addit
fewer
patient
report
sever
symptom
treatment
period
overal
reduct
proport
patient
report
symptom
rang
nasal
congest
cough
tabl
fewer
incid
sever
viral
infect
year
patient
receiv
treatment
soc
compar
previou
year
patient
receiv
soc
two
count
hospit
asthma
patient
due
sever
viral
infect
year
treatment
hospit
occur
year
patient
treat
plu
soc
patient
asthma
viral
infect
shown
import
risk
factor
wheez
patient
experienc
concomit
worsen
cough
secret
particularli
patient
expos
antigen
test
posit
allergi
screen
exhibit
late
respons
antigen
could
observ
even
week
recoveri
initi
viral
infect
recoveri
wheez
cough
secret
took
time
least
day
longer
compar
patient
wheez
episod
trigger
viral
infect
recoveri
symptom
observ
h
patient
note
detect
presenc
virus
nearli
patient
sever
asthma
crise
requir
intens
care
support
despit
optim
appropri
medic
patient
symptom
respiratori
infect
includ
spasm
secret
cough
dyspnea
decreas
satur
chest
tight
need
antibiot
administr
case
patient
asthma
viral
infect
chest
xray
find
show
distinct
interstiti
infiltr
hyperventil
frequent
aris
complic
atelectasi
bronchopneumonia
patient
asthma
bacteri
infect
identifi
strain
h
influenza
c
pneumonia
symptom
includ
sudden
fever
signific
exacerb
underli
condit
asthma
mainli
dyspnea
accompani
headach
cough
tachypnea
intercost
retract
wheez
rale
gener
malais
myalgia
loss
appetit
clinic
symptom
frequent
observ
includ
nasal
congest
odynophagia
case
accompani
hoars
ocular
congest
tear
retrostern
cough
pain
gastrointestin
symptom
includ
nausea
vomit
diarrhea
patient
present
speech
difficulti
alter
conscious
patient
exhibit
sign
immin
acut
respiratori
claudic
includ
bradycardia
absenc
wheez
paradox
thoracicoabdomin
respiratori
movement
cyanosi
sensori
depress
hospit
immedi
intens
care
unit
patient
rhiniti
exacerb
trigger
common
cold
caus
rhinovirus
virus
adenoviru
coronaviru
parainfluenza
viru
respiratori
syncyti
viru
may
also
play
role
clinic
symptom
includ
nasal
congest
pharyng
irrit
cough
wateri
rhinorrhea
sneez
symptom
consist
underli
allerg
rhiniti
although
increas
intens
frequent
accompani
fever
amount
postnas
mucu
transform
pale
erythemat
nasal
mucosa
indic
stronger
inflammatori
process
trigger
respiratori
infect
case
acut
bacteri
rhiniti
studi
symptom
copd
includ
dyspnea
chronic
cough
accompani
histori
exposur
known
risk
factor
frequent
trigger
exacerb
worsen
condit
bacteri
viral
infect
although
use
spirometri
necessari
confirm
clinic
diagnosi
copd
spirometri
recommend
exacerb
sinc
exacerb
increas
difficulti
perform
techniqu
affect
reliabl
result
order
classifi
degre
sever
copd
use
modifi
dyspnea
scale
british
medic
research
council
overal
fewer
exacerb
year
treatment
tabl
number
sever
exacerb
markedli
lower
exacerb
sever
level
count
hospit
compar
exacerb
sever
level
count
hospit
patient
receiv
plu
soc
serum
iga
level
measur
treatment
period
group
measur
taken
period
previou
year
patient
receiv
soc
group
b
compar
serum
iga
level
measur
separ
group
healthi
volunt
group
c
tabl
healthi
adult
serum
iga
level
mg
group
c
compar
mg
patient
receiv
soc
year
prior
treatment
group
b
mg
p
patient
prophylact
treatment
group
moreov
rate
increas
iga
level
group
parallel
three
cycl
therapi
shown
fig
level
salivari
secretori
iga
follow
similar
pattern
serum
iga
although
less
pronounc
increas
fig
refer
standard
use
case
colostrum
iga
mg
take
account
fact
normal
level
salivari
secretori
iga
mg
group
patient
receiv
bacteri
lysat
previou
year
receiv
soc
group
b
secretori
iga
valu
mg
patient
receiv
follow
year
group
averag
initi
valu
mg
increas
mg
p
last
day
sequenti
treatment
fig
aim
studi
assess
incid
respiratori
infect
well
symptom
exacerb
underli
medic
condit
patient
allerg
rhiniti
asthma
copd
first
studi
includ
patient
thoroughli
character
administr
patient
followedup
also
first
studi
consid
reduct
recurr
respiratori
infect
well
reduct
exacerb
patient
underli
medic
condit
name
allerg
rhiniti
asthma
copd
well
known
respiratori
infect
children
asthma
frequent
caus
respiratori
syncyti
viru
rsv
parainfluenza
viru
rhinoviru
main
trigger
adolesc
adult
larg
bodi
literatur
support
associ
viral
infect
asthma
independ
age
phenotyp
asthma
stage
viral
infect
occur
role
bacteri
infect
howev
controversi
less
wellestablish
compar
virus
note
detect
presenc
virus
nearli
patient
sever
asthma
requir
intens
care
support
among
patient
asthma
bacteri
infect
identifi
strain
h
influenza
c
pneumonia
clinic
observ
agreement
report
literatur
indic
patient
asthma
viral
infect
frequent
associ
asthma
crise
regardless
phenotyp
asthma
durat
natur
histori
diseas
bacteri
infect
lead
increas
inflamm
worsen
diseas
treatment
induc
clinic
improv
patient
affect
asthma
allerg
rhiniti
copd
term
respiratori
infect
also
respect
underli
patholog
result
show
patient
affect
asthma
allerg
rhiniti
copd
reduc
number
respiratori
infect
number
exacerb
underli
patholog
patient
report
symptom
relat
underli
medic
condit
reduc
recent
studi
demonstr
use
immunomodul
shift
respons
respons
therebi
reduc
hypersensitivityassoci
respons
predispos
patient
reduct
recurr
infect
induc
may
attribut
increas
secretori
iga
level
studi
show
secretori
iga
may
compens
igg
immunodefici
import
find
studi
increas
serum
secretori
iga
level
coincid
cycl
treatment
pattern
increas
suggest
due
treatment
induc
local
immunolog
respons
mucosa
therebi
reduc
risk
viral
bacteri
infect
background
respiratori
allerg
diseas
copd
result
studi
show
reduc
number
respiratori
tract
infect
well
number
exacerb
patient
underli
medic
condit
allerg
rhiniti
asthma
copd
expect
increas
concentr
serum
secretori
iga
seen
alongsid
improv
incid
respiratori
infect
underli
medic
condit
